Brief: Karuna Therapeutics Says Positive Results From Phase 3 Emergent-3 Trial Of KarXT In Schizophrenia

Karuna Therapeutics

20/03/2023 10:30

March 20 (Reuters) - Karuna Therapeutics Inc  KRTX.O :
    * KARUNA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM PHASE 3 EMERGENT-3
TRIAL OF
KARXT IN SCHIZOPHRENIA
    * KARUNA THERAPEUTICS: KARXT SHOWED 8.4-POINT REDUCTION IN POSITIVE AND
NEGATIVE
SYNDROME SCALE TOTAL SCORE COMPARED TO PLACEBO AT WEEK 5 (P<0.0001)
    * KARUNA THERAPEUTICS: KARXT GENERALLY WELL TOLERATED, WITH SIDE EFFECT
PROFILE
SUBSTANTIALLY CONSISTENT WITH PRIOR TRIALS OF KARXT IN SCHIZOPHRENIA
    * KARUNA THERAPEUTICS: THIRD POSITIVE REGISTRATIONAL TRIAL OF KARXT IN
SCHIZOPHRENIA MET ITS PRIMARY ENDPOINT
    * KARUNA THERAPEUTICS: ON TRACK TO SUBMIT NDA TO FDA IN MID-2023, WITH A
POTENTIAL
LAUNCH IN SECOND HALF OF 2024
    * KARUNA THERAPEUTICS: PRE-NDA MEETING IS SCHEDULED FOR EARLY SECOND QUARTER
OF
2023

Further company coverage:  KRTX.O 

 ((Reuters.Briefs@thomsonreuters.com;;))